Current situation and progress of hepatocellular carcinoma radiotherapy

doi:10.3760/cma.j.issn.1673-422X.2014.04.018

Abstract

Abstract: Radiation therapy is a primary treatment for the unresectable hepatocellular carcinoma (HCC), including internal radiotherapy, threedimensional conformal radiotherapy, threedimensional intensity modulated radiotherapy (IMRT), stereotactic radiotherapy and radiotherapy combined with transcatheter arterial chemoembolization (TACE). For small lesions, residual or recurrent lesions after external irradiation, the internal radiotherapy can purposefully place radionuclides to increase the amount of radiation in target organs and reduce the amount of radiation in normal tissue. For the patients with unclear tumor boundary, thrombosis, lymph node metastasis or local recurrence, threedimensional conformal radiotherapy, IMRT and radiotherapy combined with TACE can better make the target highdose distribution shape fit with threedimensional space accurately, and improve the local control rate.

Key words: Carcinoma, hepatocellular, Therapy, Radiotherapy

LIANG Ning, SUN Feng-Kai, ZHANG Jian-Dong. Current situation and progress of hepatocellular carcinoma radiotherapy[J]. Journal of International Oncology, 2014, 41(3): 216-220.

References

［1］ HernandezGea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma［J］. Gastroenterology, 2013, 144(3): 512527. ［2］ Herszényi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors［J］. Eur Rev Med Pharmacol Sci, 2010, 14(4): 249258. ［3］ Qian J, Luo Y, Gu X, et al. Inhibition of SENP6induced radiosensitization of human hepatocellular carcinoma cells by blocking radiationinduced NFκB activation［J］. Cancer Biother Radiopharm, 2013, 28(3): 196200. ［4］ Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium90 radioembolization for intermediateadvanced hepatocellular carcinoma: a phase 2 study［J］. Hepatology, 2013, 57(5): 18261837. ［5］ Kumar A, Srivastava DN, Chau TT, et al. Inoperable hepatocellular carcinoma: transarterial 188Re HDDlabeled iodized oil for treatmentprospective multicenter clinical trial［J］. Radiology, 2007, 243(2): 509519. ［6］ Liu MT, Li SH, Chu TC, et al. Threedimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization［J］. Jpn J Clin Oncol, 2004, 34(9): 532539. ［7］ Kim DY, Park W, Lim DH, et al. Threedimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma［J］. Cancer, 2005, 103(11): 24192426. ［8］ Kim TH, Kim DY, Park JW, et al. Threedimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable［J］. Am J Clin Oncol, 2006, 29(6): 568575. ［9］ Wang W, Feng X, Zhang T, et al. Prospective evaluation of microscopic extension using wholemount preparation in patients with hepatocellular carcinoma: definition of clinical target volume for radiotherapy［J］. Radiat Oncol, 2010, 5: 73. ［10］ Wang MH, Ji Y, Zeng ZC, et al. Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume［J］. Int J Radiat Oncol Biol Phys, 2010, 76(2): 467476. ［11］ Hallman JL, Mori S, Sharp GC, et al. A fourdimensional computed tomography analysis of multiorgan abdominal motion［J］. Int J Radiat Oncol Biol Phys, 2012, 83(1): 435441. ［12］ Dawson LA, Brock KK, Kazanjian S, et al. The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy［J］. Int J Radiat Oncol Biol Phys, 2001, 51(5): 14101421. ［13］ Yang ZX, Wang D, Wang G, et al. Clinical study of recombinant adenovirusp53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma［J］. J Cancer Res Clin Oncol, 2010, 136(4): 625630. ［14］ Tse RV, Hawkins M, Lockwood G, et al. Phase Ⅰ study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma［J］. J Clin Oncol, 2008, 26(4): 657664. ［15］ Kwon JH, Bae SH, Kim JY, et al. Longterm effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer［J］. BMC Cancer, 2010, 10: 475. ［16］ Higuchi T, Kikuchi M, Okazaki M, et al. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases［J］. Cancer, 1994, 73(9): 22592267. ［17］ Meng MB, Cui YL, Lu Y, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and metaanalysis［J］. Radiother Oncol, 2009, 92(2): 184194. ［18］ Shim SJ, Seong J, Han KH, et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma［J］. Liver Int, 2005, 25(6): 11891196. ［19］ Zhou ZH, Liu LM, Chen WW, et al. Combined therapy of transcatheter arterial chemoembolisation and threedimensional conformal radiotherapy for hepatocellular carcinoma［J］. Br J Radiol, 2007, 80(951): 194201. ［20］ Ni S, Liu L, Shu Y. Sequential transcatheter arterial chemoembolization, threedimensional conformal radiotherapy, and highintensity focused ultrasound treatment for unresectable hepatocellular carcinoma patients［J］. J Biomed Res, 2012, 26(4): 260267. ［21］ Tournoux C, Paoletti X, Barbare JC, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies［J］. Cancer Treat Rev, 2007, 33(8): 762763. ［22］ Koo JE, Kim JH, Lim YS, et al. Combination of transarterial chemoembolization and threedimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus［J］. Int J Radiat Oncol Biol Phys, 2010, 78(1): 180187.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.